Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1

Interventions

pembrolizumab 77Cyclophosphamide 50Cisplatin 47Nivolumab 37Paclitaxel 34Radiotherapy 33Carboplatin 32Gemcitabine 29Docetaxel 27Dexamethasone 24atezolizumab 23Doxorubicin 21Bevacizumab 21Etoposide 20Blood Specimen Collection 20Magnetic Resonance Spectroscopy 19Vincristine 18Radiosurgery 18Leucovorin 18Lenalidomide 18Fluorouracil 18fludarabine 17Rituximab 17Oxaliplatin 16Ipilimumab 16Cytarabine 16palbociclib 15Surveys and Questionnaires 15Radiation 15Letrozole 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × ibritumomab tiuxetan × 90 days × Clear all
NCT00690560 2026-05-22

Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

Centre Antoine Lacassagne

Phase 2 Completed
30 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡